02:07 PM EDT, 06/28/2024 (MT Newswires) -- Health care stocks were edging up Friday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) up less than 0.1%.

The iShares Biotechnology ETF (IBB) fell 0.6%.

In corporate news, CG Oncology's ( CGON ) cretostimogene immunotherapy to treat bladder cancer is expected to achieve over $4 billion in non-risk adjusted sales by 2037, BofA Securities said in a note. BofA started coverage of the company with a buy rating and a price objective of $65. CG Oncology ( CGON ) shares rose 4.8%.

Agenus ( AGEN ) shares surged 13% after the company posted results from an investigator-sponsored trial of botensilimab and balstilimab in the neoadjuvant setting for colon cancer.

Apellis Pharmaceuticals ( APLS ) shares sank past 7% after the drugmaker said it plans to seek a re-examination of the negative opinion adopted by the European Medicines Agency's Committee for Medicinal Products for Human Use on its marketing authorization application for intravitreal pegcetacoplan to treat geographic atrophy.